World's largest public-private antibiotic fund unveils first investments
The AMR Action Fund, established in the summer of 2020 by an extensive consortium of some of the world’s leading pharmaceutical companies including Novo Nordisk, is ready to announce its first two investments in the first against antimicrobial resistance (AMR).
by albert rønning-andersson, translated by daniel pedersen
Around two years after the AMR Action Fund came into existence with the goal of aiding the development of new antibiotic drugs, the fund has announced its first two investments, a press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
